Drug: |
||||
---|---|---|---|---|
Trial Name: |
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) |
|||
NCT#: |
||||
Conditions: |
Sarcoma |
|||
Status: |
Recruiting |
|||
Phase: |
2 |
Start Date 07/27/2021 |
Age of Trial (yrs) .8 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
FGFR inhibitor |
|||
Strategy: |
Block FGFR Pathway |
|||
Trial Type: |
Specifically GIST plus other cancers |
|||
Other Protocol IDs: |
NCI-2020-08011 |
|||
Sponsor: |
National Cancer Institute (NCI) |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
Inclusion Criteria: Participant must have histologically confirmed sarcoma with FGFR alteration identified by next-generation sequencing profiling with the exception of SDH-deficient GIST who can be enrolled regardless of FGFR status. Initial testing can be performed on archival tissue Presence of measurable disease: Patient must have measurable disease Patients must have progressed following at least one standard prior chemotherapy regimen with the exception of SDH-deficient GIST for which there is no standard of care |
Trial Links |
Trial Results |
Drug Information |
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models |
Name |
Address |
City |
State |
Zip |
Country |
450 Brookline Ave |
Boston |
MA |
02215-5450 |
USA |
|
Building 10, Room 4-3760 |
Bethesda |
MD |
20892 |
USA |
|
1500 E. Duarte Road |
Duarte |
CA |
91010 |
USA |
|
1275 York Ave |
New York |
NY |
10065 |
USA |
|
660 S. Euclid Ave |
St. Louis |
MO |
63110 |
USA |
|
Pittsburgh |
PA |
15232 |
USA |